GlassScriptPhysician profile
Jennifer A Thomas
NPI 1346355450
$7,363.21
in general payments reported to CMS, 2019-2025
28 companies · $3,024 in 2025
The $3,024 reported for 2025 was more than what 95% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
See the full distribution for Adult Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $446 · 2022: $658 · 2023: $979 · 2024: $2,256 · 2025: $3,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,259.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,513.21 | 2021-2025 | |
| Janssen Biotech, INC. | $1,136.08 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,066.32 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Phathom Pharmaceuticals, INC. | $637.36 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $395.47 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $312.44 | 2024-2025 | Ibsrela |
| Braintree Laboratories, INC. | $277.75 | 2021-2025 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $273.51 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246.53 | 2021-2025 | Xifaxan |
| Pfizer INC. | $220.77 | 2022-2025 | |
| Lilly USA, LLC | $188.76 | 2025 | Zepbound, Omvoh |
| Ferring Pharmaceuticals INC. | $167.45 | 2021-2024 | Rebyota |
| Genzyme Corporation | $150.02 | 2022-2025 | |
| Gilead Sciences, INC. | $136.03 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $114.67 | 2023 | Stelara |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $93.48 | 2023-2025 | Dupixent |
| Celltrion USA INC. | $81.89 | 2024-2025 | Vegzelma, Zymfentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.16 | 2023-2024 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $48.45 | 2021-2024 | |
| Albireo Pharma, INC. | $44.80 | 2024 | Bylvay, Iqirvo |
| Intercept Pharmaceuticals, INC. | $29.38 | 2021-2022 | |
| Ucb, INC. | $29.10 | 2024 | Cimzia |
| Merck Sharp & Dohme LLC | $28.62 | 2023 | Dificid, Zinplava |
| Redhill Biopharma INC. | $28.58 | 2021-2022 | |
| Organon LLC | $26.12 | 2022-2025 | Renflexis, Hadlima |
| Evoke Pharma, INC. | $22.76 | 2024 | |
| Novo Nordisk INC | $18.79 | 2025 | Wegovy |
| Amgen INC. | $16.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.